Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Possibilities and challenges for developing a successful vaccine for leishmaniasis
Saumya Srivastava, Prem Shankar, Jyotsna Mishra, et al.
Parasites & Vectors (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 185

Showing 1-25 of 185 citing articles:

Functions of ROS in Macrophages and Antimicrobial Immunity
Marc Herb, Michael Schramm
Antioxidants (2021) Vol. 10, Iss. 2, pp. 313-313
Open Access | Times Cited: 436
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Mark C. Field, David Horn, Alan H. Fairlamb, et al.
Nature Reviews Microbiology (2017) Vol. 15, Iss. 4, pp. 217-231
Open Access | Times Cited: 398
Leishmaniasis in humans: drug or vaccine therapy?
Masoud Ghorbani, Ramin Farhoudi
Drug Design Development and Therapy (2017) Vol. Volume 12, pp. 25-40
Open Access | Times Cited: 322
Macrophage Polarization in Leishmaniasis: Broadening Horizons
Fernanda Tomiotto‐Pellissier, Bruna Taciane da Silva Bortoleti, João Paulo Assolini, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 188
Leishmania vaccines entered in clinical trials: A review of literature
Hossein Rezvan, Mohammad Moafi, Roya Sherkat, et al.
International Journal of Preventive Medicine (2019) Vol. 10, Iss. 1, pp. 95-95
Open Access | Times Cited: 128
Nanostructured delivery systems with improved leishmanicidal activity: a critical review
Natascia Bruni, Barbara Stella, Leonardo Giraudo, et al.
International Journal of Nanomedicine (2017) Vol. Volume 12, pp. 5289-5311
Open Access | Times Cited: 101
Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges
Kiran Saleem, Zainab Khursheed, Christophe Hano, et al.
Nanomaterials (2019) Vol. 9, Iss. 12, pp. 1749-1749
Open Access | Times Cited: 94
Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future
Raşit Dinç
Korean Journal of Parasitology (2022) Vol. 60, Iss. 6, pp. 379-391
Open Access | Times Cited: 42
Global Dilemma and Needs Assessment Toward Achieving Sustainable Development Goals in Controlling Leishmaniasis
Mehdi Bamorovat, Iraj Sharifi, Ahmad Khosravi, et al.
Journal of Epidemiology and Global Health (2024) Vol. 14, Iss. 1, pp. 22-34
Open Access | Times Cited: 12
The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases
Nnamdi Ikemefuna Okafor, Omobolanle A. Omoteso, Yahya E. Choonara
Discover Nano (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum
Bahareh Vakili, Mahboobeh Eslami, Gholamreza Hatam, et al.
International Journal of Biological Macromolecules (2018) Vol. 120, pp. 1127-1139
Closed Access | Times Cited: 74
Interplay of Regulatory T Cell and Th17 Cells during Infectious Diseases in Humans and Animals
Sharvan Sehrawat, Barry T. Rouse
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 70
Leishmania Immunity: Advancing Immunotherapy and Vaccine Development
Nnamdi Ikeogu, Gloria N. Akaluka, Chidalu A. Edechi, et al.
Microorganisms (2020) Vol. 8, Iss. 8, pp. 1201-1201
Open Access | Times Cited: 69
The enemy within: Targeting host–parasite interaction for antileishmanial drug discovery
Suzanne Lamotte, Gérald F. Späth, Najma Rachidi, et al.
PLoS neglected tropical diseases (2017) Vol. 11, Iss. 6, pp. e0005480-e0005480
Open Access | Times Cited: 64
Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight
Humzah Jamshaid, Fakhar ud Din, Gul Majid Khan
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 53
From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection
Greta Volpedo, Ryan H. Huston, Erin A. Holcomb, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 11, pp. 1431-1446
Open Access | Times Cited: 47
Leishmania vaccine development: A comprehensive review
Isha Saini, Jyoti Joshi, Sukhbir Kaur
Cellular Immunology (2024) Vol. 399-400, pp. 104826-104826
Closed Access | Times Cited: 8
Skin parasite landscape determines host infectiousness in visceral leishmaniasis
Johannes S. P. Doehl, Zoe Bright, Shoumit Dey, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Innovations for the elimination and control of visceral leishmaniasis
Angamuthu Selvapandiyan, Simon L. Croft, Suman Rijal, et al.
PLoS neglected tropical diseases (2019) Vol. 13, Iss. 9, pp. e0007616-e0007616
Open Access | Times Cited: 47
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection
Daniela P. Lage, Patrícia A.F. Ribeiro, Daniel Dias, et al.
npj Vaccines (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 43
Immunotherapy in treatment of leishmaniasis
Maryam Akbari, Ahmad Oryan, Gholamreza Hatam
Immunology Letters (2021) Vol. 233, pp. 80-86
Closed Access | Times Cited: 34
The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates
Greta Volpedo, Parna Bhattacharya, Sreenivas Gannavaram, et al.
Pathogens (2022) Vol. 11, Iss. 4, pp. 431-431
Open Access | Times Cited: 27
Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
Ganesh Yadagiri, Aakriti Singh, Kanika Arora, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 14
Nerolidol, the main constituent of Piper aduncum essential oil, has anti-Leishmania braziliensis activity
Lígia Fernanda Ceole, María das Graças Cardoso, Maurílio José Soares
Parasitology (2017) Vol. 144, Iss. 9, pp. 1179-1190
Closed Access | Times Cited: 44
Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis
Daniel Dias, Patrícia A.F. Ribeiro, Vívian T. Martins, et al.
Translational research (2018) Vol. 200, pp. 18-34
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top